Literature DB >> 2023270

Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome.

M H Gail1, J M Pluda, C S Rabkin, R J Biggar, J J Goedert, J W Horm, E J Sondik, R Yarchoan, S Broder.   

Abstract

Advances in antiretroviral therapy and treatment or prophylaxis against opportunistic infection have resulted in prolongation of the survival of patients with acquired immunodeficiency syndrome (AIDS). Previous research has demonstrated an association between AIDS and risk of non-Hodgkin's lymphoma (NHL). In addition to the approximately 3% of individuals found to have NHL at the time of AIDS onset, others continue to develop NHL following AIDS diagnosis. Data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute demonstrated a sharply increasing incidence of NHL among men in the age range 20-49 years since 1983 in the United States. Based on new data on the risk of NHL following AIDS diagnosis, on estimates of improved survival following AIDS diagnosis, and on projections of future AIDS incidence, we considered four sets of assumptions and estimated the number of AIDS-related NHL cases in 1992 to be between 2900 and 9800. Three of these projections were higher than the estimate of 4700 cases obtained by linear extrapolation of SEER incidence trends. These projections of AIDS-related NHL incidence suggest that between 8% and 27% of all NHL cases that occur in the United States in 1992 will arise as a consequence of infection with the human immunodeficiency virus (HIV), imposing a substantial health care burden. More research into the pathogenesis of lymphoma and new approaches to antiretroviral and antilymphoma therapy will be necessary to prevent and treat this formidable complication of infection with HIV.

Entities:  

Mesh:

Year:  1991        PMID: 2023270     DOI: 10.1093/jnci/83.10.695

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  17 in total

1.  Non-acquired immune deficiency syndrome-defining malignancies in a hospital-based cohort of human immunodeficiency virus-infected patients: Bordeaux, France, 1985-1991. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

Authors:  M Hajjar; D Lacoste; G Brossard; P Morlat; M Dupon; L R Salmi; F Dabis
Journal:  J Natl Cancer Inst       Date:  1992-10-21       Impact factor: 13.506

2.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  Descriptive epidemiology of ophthalmic and ocular adnexal non-Hodgkin's lymphoma.

Authors:  Roxana Moslehi; F Bruce Coles; Maria J Schymura
Journal:  Expert Rev Ophthalmol       Date:  2011

4.  Gene therapy for HIV infections: Intracellular immunization.

Authors:  A Piché
Journal:  Can J Infect Dis       Date:  1999-07

5.  HIV and the necropsy.

Authors:  S B Lucas
Journal:  J Clin Pathol       Date:  1993-12       Impact factor: 3.411

6.  Amplified RPS6KB1 and CDC2 genes are potential biomarkers for aggressive HIV+/EBV+ diffuse large B-cell lymphomas.

Authors:  Xianfeng F Zhao; Merry Y Zhao; Ling Chai; Debra Kukuruga; Ming Tan; Sanford A Stass
Journal:  Int J Clin Exp Pathol       Date:  2013-01-15

Review 7.  Malignant tumours in patients with HIV infection.

Authors:  U Tirelli; S Franceschi; A Carbone
Journal:  BMJ       Date:  1994-04-30

Review 8.  HIV-mediated B-lymphocyte activation and lymphomagenesis.

Authors:  J G Monroe; L E Silberstein
Journal:  J Clin Immunol       Date:  1995-03       Impact factor: 8.317

Review 9.  Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity.

Authors:  G Gaidano; C Pastore; C Lanza; U Mazza; G Saglio
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

10.  Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma.

Authors:  J A Sparano; P H Wiernik; X Hu; C Sarta; D H Henry; H Ratech
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.